Mark N. Cruickshank

1.2k total citations
24 papers, 722 citations indexed

About

Mark N. Cruickshank is a scholar working on Molecular Biology, Immunology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Mark N. Cruickshank has authored 24 papers receiving a total of 722 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Molecular Biology, 10 papers in Immunology and 4 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Mark N. Cruickshank's work include Epigenetics and DNA Methylation (7 papers), Immunotherapy and Immune Responses (6 papers) and Immune Cell Function and Interaction (5 papers). Mark N. Cruickshank is often cited by papers focused on Epigenetics and DNA Methylation (7 papers), Immunotherapy and Immune Responses (6 papers) and Immune Cell Function and Interaction (5 papers). Mark N. Cruickshank collaborates with scholars based in Australia, United States and Finland. Mark N. Cruickshank's co-authors include Jeffrey M. Craig, Richard Saffery, Lavinia Gordon, Miina Ollikainen, David Martino, Daniela Ulgiati, Yuk Jing Loke, Lawrence J. Abraham, Jihoon E. Joo and Boris Novakovic and has published in prestigious journals such as Oncogene, Biochemical and Biophysical Research Communications and Genome Research.

In The Last Decade

Mark N. Cruickshank

24 papers receiving 708 citations

Peers

Countries citing papers authored by Mark N. Cruickshank

Since Specialization

Citations

This map shows the geographic impact of Mark N. Cruickshank's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark N. Cruickshank with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark N. Cruickshank more than expected).

Fields of papers citing papers by Mark N. Cruickshank

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark N. Cruickshank. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark N. Cruickshank. The network helps show where Mark N. Cruickshank may publish in the future.

Co-authorship network of co-authors of Mark N. Cruickshank

This figure shows the co-authorship network connecting the top 25 collaborators of Mark N. Cruickshank. A scholar is included among the top collaborators of Mark N. Cruickshank based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark N. Cruickshank. Mark N. Cruickshank is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Single cell transcriptomics reveals cell type specific features of developmentally regulated responses to lipopolysaccharide between birth and 5 years 2023 ·Frontiers in Immunology ·(unknown), Michael Serralha, (unknown), Muhammad Munir Iqbal, Mark N. Cruickshank, Alka Saxena, Deborah H. Strickland, Jason Waithman, Patrick G. Holt, Anthony Bosco	3
2	Lipopolysaccharide-induced interferon response networks at birth are predictive of severe viral lower respiratory infections in the first year of life 2022 ·Frontiers in Immunology ·(unknown), Michael Serralha, D. Mok, Barbara J. Holt, Mark N. Cruickshank, Yuliya V. Karpievitch, David Broadhurst, Peter D. Sly, Deborah H. Strickland, Stacey N. Reinke, Patrick G. Holt, Anthony Bosco	4
3	IFNβ Is a Potent Adjuvant for Cancer Vaccination Strategies 2021 ·Frontiers in Immunology ·(unknown), Teagan Wagner, (unknown), (unknown), Anthony Buzzai, (unknown), Ben Wylie, (unknown), Tsuneyasu Kaisho, Anthony Bosco, Alison M. McDonnell, Mark N. Cruickshank, Vanessa S. Fear, Bree Foley, Jason Waithman	18
4	Notch signaling induces a transcriptionally permissive state at the Complement C3d Receptor 2 (CR2) promoter in a pre-B cell model 2020 ·Molecular Immunology ·(unknown), Rhonda L. Taylor, (unknown), Lawrence J. Abraham, Elizabeth Quail, Mark N. Cruickshank, Daniela Ulgiati	2
5	Identifying the optimal donor for natural killer cell adoptive therapy to treat paediatric B‐ and T‐cell acute lymphoblastic leukaemia 2020 ·Clinical & Translational Immunology ·Bree Foley, (unknown), (unknown), Emma de Jong, Michelle Nguyen, Laurence C. Cheung, Anthony Buzzai, Teagan Wagner, Ben Wylie, Sònia Fernández, Mark N. Cruickshank, Raelene Endersby, Ursula R. Kees, Jason Waithman	9
6	CD8+XCR1neg Dendritic Cells Express High Levels of Toll-Like Receptor 5 and a Unique Complement of Endocytic Receptors 2019 ·Frontiers in Immunology ·Ben Wylie, (unknown), Anthony Buzzai, Teagan Wagner, Niamh Troy, (unknown), Shane R. Stone, Bree Foley, Anthony Bosco, Mark N. Cruickshank, Jason Waithman	10
7	Impaired T cell proliferation byex vivoBET-inhibition impedes adoptive immunotherapy in a murine melanoma model 2019 ·Epigenetics ·Jonathan Chee, (unknown), Anthony Buzzai, Ben Wylie, Catherine A. Forbes, (unknown), (unknown), Bree Foley, Mark N. Cruickshank, Jason Waithman	6
8	Tumor penetrating peptides inhibiting MYC as a potent targeted therapeutic strategy for triple-negative breast cancers 2018 ·Oncogene ·Edina Wang, Anabel Sorolla, (unknown), (unknown), Samuel J. Beck, Emily Golden, Robert E. Dewhurst, Laura V. Flórez, Mark N. Cruickshank, Katrin Hoffmann, R.M. Hopkins, Jonghwan Kim, Andrew J. Woo, Paul M. Watt, Pilar Blancafort	67
9	Systematic chemical and molecular profiling of MLL-rearranged infant acute lymphoblastic leukemia reveals efficacy of romidepsin 2016 ·Leukemia ·Mark N. Cruickshank, Jette Ford, Laurence C. Cheung, (unknown), (unknown), (unknown), (unknown), Greg M. Arndt, Nicholas Smithers, Rab K. Prinjha, Denise Anderson, Kim W. Carter, Alexander M. Gout, Timo Lassmann, John O’Reilly, Catherine Cole, Rishi S. Kotecha, Ursula R. Kees	18
10	Analysis of tandem E-box motifs within human Complement receptor 2 (CR2/CD21) promoter reveals cell specific roles for RP58, E2A, USF and localized chromatin accessibility 2015 ·The International Journal of Biochemistry & Cell Biology ·Mark N. Cruickshank, (unknown), Rhonda L. Taylor, (unknown), (unknown), Elizabeth Quail, (unknown), V. Michael Holers, Lawrence J. Abraham, Daniela Ulgiati	3
11	Focused transcription from the human CR2/CD21 core promoter is regulated by synergistic activity of TATA and Initiator elements in mature B cells 2015 ·Cellular and Molecular Immunology ·Rhonda L. Taylor, Mark N. Cruickshank, (unknown), (unknown), Elizabeth Quail, Kenneth M. Kaufman, John B. Harley, Lawrence J. Abraham, Betty P. Tsao, Susan A. Boackle, Daniela Ulgiati	1
12	Analysis of epigenetic changes in survivors of preterm birth reveals the effect of gestational age and evidence for a long term legacy 2013 ·Genome Medicine ·Mark N. Cruickshank, Alicia Oshlack, Christiane Theda, Peter G. Davis, David Martino, Penelope M. Sheehan, Yun Dai, Richard Saffery, Lex W. Doyle, Jeffrey M. Craig	83
13	Transcriptional effects of a lupus-associated polymorphism in the 5′ untranslated region (UTR) of human complement receptor 2 (CR2/CD21) 2012 ·Molecular Immunology ·Mark N. Cruickshank, (unknown), (unknown), (unknown), Tim R. Mercer, Betty P. Tsao, Susan A. Boackle, Daniela Ulgiati	12
14	Neonatal DNA methylation profile in human twins is specified by a complex interplay between intrauterine environmental and genetic factors, subject to tissue-specific influence 2012 ·Genome Research ·Lavinia Gordon, Jihoon E. Joo, Joseph E. Powell, Miina Ollikainen, Boris Novakovic, Xin Li, Roberta Andronikos, Mark N. Cruickshank, Karen N. Conneely, Alicia K. Smith, Reid S. Alisch, Ruth Morley, Peter M. Visscher, Jeffrey M. Craig, Richard Saffery	180
15	Going back to the future with Guthrie-powered epigenome-wide association studies 2012 ·Genome Medicine ·Mark N. Cruickshank, James Pitt, Jeffrey M. Craig	16
16	The impact of histone post-translational modifications on developmental gene regulation 2010 ·Amino Acids ·Mark N. Cruickshank, Paul G. Besant, Daniela Ulgiati	22
17	Cell- and stage-specific chromatin structure across the Complement receptor 2 (CR2/CD21) promoter coincide with CBF1 and C/EBP-β binding in B cells 2009 ·Molecular Immunology ·Mark N. Cruickshank, (unknown), (unknown), Lawrence J. Abraham, Daniela Ulgiati	7
18	A critical assessment of the factors affecting reporter gene assays for promoter SNP function: a reassessment of −308 TNF polymorphism function using a novel integrated reporter system 2009 ·European Journal of Human Genetics ·(unknown), Lauren C. Goldie, Mark N. Cruickshank, Eric K. Moses, Lawrence J. Abraham	48
19	The role of notch signaling in the development of a normal B‐cell repertoire 2009 ·Immunology and Cell Biology ·Mark N. Cruickshank, Daniela Ulgiati	19
20	Quantitative differences in chromatin accessibility across regulatory regions can be directly compared in distinct cell-types 2007 ·Biochemical and Biophysical Research Communications ·Mark N. Cruickshank, (unknown), Lawrence J. Abraham, Daniela Ulgiati	17

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact